Knowledge production and commercialization from R&D: the pharmaceutical sector

Statistics
Metrics and citations
Metadata
Show full item recordDate
2023Department
Economía Financiera y Contabilidad; Organización de EmpresasSource
Management Decision, Vol. 61 No. 13, 2023 pp. 222-247Abstract
Purpose – The objective of this work is to demonstrate the relationships between the two main processes of
research and development (R&D) activities: the knowledge generation phase (KPP) and the knowledge
commercialization, or transfer, phase (KCP), in a sector that is intensive in this type of activity, such as the
pharmaceutical sector. In addition, within the framework of the general objective of this work, the authors propose
two other objectives: (1) make advances in network efficiency measurement models, and (2) determine the factors
associated with efficiency in the KPP and in the KCP in companies of the pharmaceutical sector in Spain.
Design/methodology/approach – A Network Data Envelopment Analysis (NDEA) model (F€are and
Grosskopf, 2000) with categorical variables (Lee et al., 2020; Yeh and Chang, 2020) has been applied, and a
sensitivity analysis of the obtained results has been performed through a DEA model of categorical variables,
in accordance with the work of Banker and Morey (1986), to corroborate the results of the proposed model. The
sample is made up of 77 companies in the pharmaceutical sector in Spain.
Findings – The results obtained point to a greater efficiency of pharmaceutical companies in the KPP, rather
than in the KCP. Furthermore, the study finds that 1) alliances between companies have been the accelerating
factors of efficiency in the KCP (but patents have slowed this down the most); 2) the quality of R&D and the
number of R&D personnel are the factors that most affect efficiency in the KPP; and 3) the quality of R&D
again, the benefits obtained and the position in the market are the factors that most affect efficiency in the KCP.
Originality/value – The authors have not found studies that show whether the efficiency obtained by R&Dintensive
companies in theKPP phase is related to better results in terms of efficiency in theKCP phase.Nopapers
have been found that analyse the role of alliances between R&D-intensive companies and patents, as agents that
facilitate efficiency in the KCP phase, covering the gap in the research on both problems. Notwithstanding, this
work opens up a research path which is related to the improvement of network efficiencymodels (since it includes
categorical variables) and the assessment of the opinions of those who are responsible for R&D departments; it
can be applied to decision-making on the aspects to improve efficiency in R&D-intensive companies.
Subjects
R&D activities; Efficiency; Pharmaceutical sector; Network DEACollections
- Artículos Científicos [11977]
- Articulos Científicos Ec. Fin. Cont. [82]
- Artículos Científicos INDESS [1043]
- Articulos Científicos Org. Emp. [291]






